Relevant bibliographies by topics / Polycystic ovary syndrome Pathophysiology

Academic literature on the topic 'Polycystic ovary syndrome Pathophysiology'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Polycystic ovary syndrome Pathophysiology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Polycystic ovary syndrome Pathophysiology"

1

Mauvais-Jarvis, Pierre, and Claire Bricaire. "Pathophysiology of polycystic ovary syndrome." Journal of Steroid Biochemistry 33, no. 4 (October 1989): 791–94. http://dx.doi.org/10.1016/0022-4731(89)90494-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Taketani, Yuji. "Pathophysiology of Polycystic Ovary Syndrome." Hormone Research 33, no. 2 (1990): 3–4. http://dx.doi.org/10.1159/000181556.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tsilchorozidou, Tasoula, Caroline Overton, and Gerard S. Conway. "The pathophysiology of polycystic ovary syndrome." Clinical Endocrinology 60, no. 1 (January 2004): 1–17. http://dx.doi.org/10.1046/j.1365-2265.2003.01842.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Whitaker, Kristin Nadine. "Polycystic Ovary Syndrome." Journal of Pharmacy Practice 24, no. 1 (November 30, 2010): 94–101. http://dx.doi.org/10.1177/0897190010384632.

Full text
Abstract:
Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age. It affects 6% to 7% of the population and is characterized by hyperandrogenism and ovarian dysfunction. Women with the disorder often present with insulin resistance and obesity, making it importance for health care providers to monitor closely for signs and symptoms of metabolic syndrome and type 2 diabetes. Treatments are targeted toward improving insulin tolerance, reducing signs and symptoms of hyperandrogenism (hirsutism, anovulation, etc), restoring normal menstrual cycle function, and restoring fertility. Major treatment should include weight management through diet and exercise, regardless of body mass index and might include concurrent drug therapy. It is important that pharmacists understand the underlying pathophysiology of the disease and the available treatments, in addition to the importance of reducing risk of metabolic syndrome/type 2 diabetes, and cardiovascular disease in these patients.
APA, Harvard, Vancouver, ISO, and other styles
5

Guzick, David. "Polycystic ovary syndrome: Symptomatology, pathophysiology, and epidemiology." American Journal of Obstetrics and Gynecology 179, no. 6 (December 1998): S89—S93. http://dx.doi.org/10.1016/s0002-9378(98)70238-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Platt, Terrie H. "Polycystic ovary syndrome: Diagnosis and management." Women’s Healthcare: A Clinical Journal for NPs 10, no. 5 (October 12, 2022): 08–42. http://dx.doi.org/10.51256/whc102208.

Full text
Abstract:
The author reviews prevalence, pathophysiology, assessment and diagnostic considerations, and treatment options for polycystic ovary syndrome to help nurse practitioners recognize it and provide evidence-based patient counseling and management.
APA, Harvard, Vancouver, ISO, and other styles
7

Cunningham, Priscilla. "Pathophysiology, diagnosis and treatment of polycystic ovary syndrome." Nursing Standard 31, no. 39 (May 24, 2017): 44–51. http://dx.doi.org/10.7748/ns.2017.e10595.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Spritzer, Poli, Carolina Barone, and Fabiana Oliveira. "Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management." Current Pharmaceutical Design 22, no. 36 (November 11, 2016): 5603–13. http://dx.doi.org/10.2174/1381612822666160720151243.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

C., Muhas, Nishad K. M., Ummunnoora K. P., Jushna K., Saheera K. V., and Dilsha K. P. "POLYCYSTIC OVARY SYNDROME (PCOS)–AN OVERVIEW." International Journal of Current Pharmaceutical Research 10, no. 6 (November 30, 2018): 5. http://dx.doi.org/10.22159/ijcpr.2018v10i6.30969.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is one of most common female endocrine disorder that affects 6-15% of the female population. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health and appearance. Androgen excess and insulin resistance are currently recognized to be responsible for much of the phenotypic presentation, though insulin resistance is far from universally present. It is characterized by irregular menstrual cycle, acne and also associated with type-2 diabetes mellitus and cardiovascular disease. Efficient management of PCOS provides a prospective window of opportunity to avoid the risk of associated complications. Treatment is broadly aimed at tackling (IR), effects of hyperandrogenism, irregular menstruation, and infertility. This review article mainly deals with the etiology, pathophysiology, diagnosis and management of Polycystic ovary syndrome.
APA, Harvard, Vancouver, ISO, and other styles
10

Soni, Abhishek, Shivali Singla, and Sachin Goyal. "POLYCYSTIC OVARY SYNDROME: PATHOGENESIS, TREATMENT AND SECONDARY ASSOCIATED DISEASES." Journal of Drug Delivery and Therapeutics 8, no. 5 (September 6, 2018): 107–12. http://dx.doi.org/10.22270/jddt.v8i5.1892.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. It is characterized by hyperandrogenism, polycystic ovaries, and chronic anovulation along with insulin resistance, hyperinsulinemia, abdominal obesity, hypertension, and dyslipidemia as frequent metabolic traits (metabolic syndrome) that culminate in serious long-term consequences such as type 2 diabetes mellitus, endometrial hyperplasia, and coronary artery disease. It is one of the most common causes of anovulatory infertility. A complete understanding of the underlying Pathophysiology of PCOS is still lacking. Because of the heterogeneity of this disorder, there are most likely multiple underlying pathophysiologic mechanisms. Pathogenesis of PCOS is explaining as alteration in gonadotropin-releasing hormone secretion results in increased luteinizing hormone (LH) secretion. An alteration in insulin secretion and insulin action results in hyperinsulinemia and insulin resistance. A defect in androgen synthesis that results in increased ovarian androgen production.Treatment of PCOS include maintaining a normal endometrium, antagonizing the actions of androgens on target tissues, reducing insulin resistance (when present), and correcting anovulation. Women with polycystic ovary syndrome (PCOS) are at higher risk for several other health conditions as Insulin Resistance, Metabolic Syndrome, Type 2 Diabetes, Obesity, Heart Disease and High Blood Pressure (Cardiovascular Disease)
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Polycystic ovary syndrome Pathophysiology"

1

Bützow, Tarja. "Gonadotropins and metabolic features in the pathophysiology and treatment of polycystic ovary syndrome." Helsinki : University of Helsinki, 2000. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/butzow/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Patterson, Moneka Angilene. "Polycystic Ovary Syndrome Treatment." ScholarWorks, 2017. https://scholarworks.waldenu.edu/dissertations/4319.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is an endocrine system disorder that affects women of reproductive age. If not treated properly, PCOS can lead to infertility. Lack of proper treatment of PCOS may also result in medical complications such as diabetes or heart disease. The rural clinic where this project took place did not have a mandatory guideline for treatment of PCOS; therefore, no standardized method of diagnosis or treatment of PCOS existed. The purpose of this project, guided by the IOWA evidence-based practice model, was to educate providers on the evidence-based guideline for diagnosis and treatment of PCOS outlined by the Endocrine Society Taskforce. The guideline was selected after a comprehensive literature review and was used to develop an educational program that was provided to 5 nurse practitioners, the medical director and staff. A pre-test post-test design was used to determine if the participants understood the content from the guideline that was presented. Results showed that the researcher-developed test administered to participants yielded scores of 74 on the pre-test and increased after the education program with all participants scoring 100 on the post-test. The guideline used for the education was then presented to the clinic for implementation with the assistance of the medical director's support. The project provided an evidence-based guideline for diagnosing and treating PCOS and raised awareness of PCOS among all staff in a rural clinic where many patients with PCOS are treated. Positive social change may result as providers are better prepared to deliver evidence-based care for PCOS and as infertility and complications of untreated PCOS are reduced.
APA, Harvard, Vancouver, ISO, and other styles
3

Morin-Papunen, L. (Laure). "Insulin resistance in polycystic ovary syndrome." Doctoral thesis, University of Oulu, 2000. http://urn.fi/urn:isbn:9514257405.

Full text
Abstract:
Abstract The polycystic ovary syndrome, described first as the association of bilateral polycystic ovaries and amenorrhoea, oligomenorrhoea, hirsutism and obesity, was later shown to be a complex metabolic syndrome. The first purpose of this study was to investigate the occurrence of hyperinsulinaemia and the severity of insulin resistance and glucose tolerance disorders in polycystic ovary syndrome by means of the oral glucose tolerance test and the euglycaemic hyperinsulinaemic clamp. The next goal was to investigate whether women with polycystic ovary syndrome would benefit from insulin-sensitising drugs, and in particular to compare the effects of metformin and a contraceptive pill containing ethinyl oestradiol and cyproterone acetate. Altogether, 81 women with polycystic ovary syndrome and 34 healthy control subjects were involved in the study. Marked impairment of insulin sensitivity in obese subjects with polycystic ovary syndrome, including a decrease of both cellular oxidative and non-oxidative utilisation of glucose, and a slight non-significant decrease of insulin sensitivity in non-obese subjects was observed. Both non-obese and obese subjects with polycystic ovary syndrome exhibited increased abdominal obesity compared with the controls, confirming the fact that obesity, in particular abdominal obesity, is an important contributor in the development of insulin resistance in this syndrome. Metformin alleviated hyperandrogenism by essentially decreasing ovarian, but not adrenal androgen secretion. The improvement of hyperandrogenism and ovarian function seemed to be mediated by the improvement of hyperinsulinaemia, which resulted itself from subtle improvements in both hepatic insulin extraction and insulin sensitivity. Metformin decreased abdominal obesity and the release of free fatty acids from adipose tissue, and improved ovarian cyclicity and fertility. The transient decrease in serum leptin levels observed may have some role in the improvement of ovarian function. The contraceptive pill significantly improved hyperandrogenism and hirsutism, and it slightly affected glucose metabolism. Thus, it could be the treatment of choice in women with hirsutism problems and no fertility hopes. Metformin could be the drug of choice for women with polycystic ovary syndrome who wish to conceive. Because of its beneficial metabolic effects, the value of metformin in reducing the risk of cardiovascular diseases in polycystic ovary syndrome needs to be further studied.
APA, Harvard, Vancouver, ISO, and other styles
4

Cho, Li Wei. "Cardiometabolic aspects of polycystic ovary syndrome." Thesis, University of Hull, 2008. http://hydra.hull.ac.uk/resources/hull:5826.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6-7% of the population. It is characterised by chronic anovulation and hyperandrogenism with the clinical manifestation of oligomenorrhoea, hirsutism and acne. A ten to twenty fold increased risk for type 2 diabetes in PCOS patients compared to weight matched female control subjects makes the syndrome of high socioeconomic importance. The use of differing diagnostic criteria makes the comparison of studies on PCOS difficult until harmonisation through the Rotterdam consensus in 2004. Despite being removed from the diagnostic criteria by the the Rotterdam consensus, the LH/FSH ratio is still widely used as one of the diagnostic criteria for PCOS. Therefore to determine the usefulness of the LH/FSH ratio in the diagnosis of PCOS, I have conducted a study as described in chapter two and showed that an elevated LH to FSH ratio was as commonly found in normal women as those with PCO, and therefore of no diagnostic value. In January 2004, the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) co-sponsored the Rotterdam polycystic ovary syndrome consensus workshop that published diagnostic guidelines, building on the consensus statement of the National Institutes of Health 1990. The Rotterdam criteria for the diagnosis of PCOS states 2 of the 3 features needs to be present to make the diagnosis, and with the exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Gushing's syndrome). These features include (l)Oligo- or anovulation (2)Clinical and/or biochemical signs of hyperandrogenism and (3)Polycystic ovaries (either 12 or more follicles measuring 2-9 mm in diameter, or an ovarian volume of > 10 cm³ ). Following the introduction of this guideline, the diagnosis of PCOS in patients recruited for studies on PCOS have been standardised. However, the current biochemical test for hyperandrogenism in women is still not ideal, due to the variation in the assay at low values. All three of total testosterone, bioavailable testosterone and free androgen index (FAI) are currently used as markers of hyperandrogenism for the diagnosis of PCOS. In chapter three, I evaluated the variability of each of the three markers as well as their use in the diagnosis and monitoring patients with PCOS and found that FAI is a better diagnostic marker for hyperandrogenism in patients with PCOS, but once the diagnosis is made, all three methods are equally good in monitoring disease progression. It has now been recognised that the diagnosis of metabolic syndrome identifies patients at increased risk of developing cardiovascular disease, and attempts have been made to develop the most convenient and useful criteria for the diagnosis of this condition in clinical practice. With the pathogenesis of metabolic syndrome not well understood, central obesity and insulin resistance are acknowledged as important causative factors. Cardiovascular disease studies in PCOS had so far been inconclusive with some suggesting increased cardiac events among women with PCOS whilst other studies suggesting no increase compared with normal cycling women. This may be attributed to small sample size in studies and variation in characteristics of patients recruited as well as surrogate markers used. C-reactive protein (CRP) had been widely used as a marker of inflammation, endothelial dysfunction and risk of cardiovascular disease in general and in patients with PCOS. However, there had not been any studies on the biovailability of this marker as the potential utility of CRP as a marker of cardiovascular risk may be limited by the magnitude of this variability in both health and disease, since there can be substantial overlap between PCOS and control individuals. In chapter four, the biological variation of high sensitivity CRP in women with PCOS were compared to normal menstruating women. I found that while the mean concentration of CRP was higher in individuals with PCOS compared to healthy controls, the intraindividual variation of CRP was similarly large in both groups. Therefore, the potential utility of CRP as a marker of cardiovascular risk may be limited by the magnitude of this variability in both health and disease, since there can be substantial overlap between PCOS and control individuals. PCOS is associated with a high risk of progression to type 2 diabetes (T2DM) and impaired glucose tolerance. A history of T2DM in a first-degree relative appears to define a subset of PCOS subjects with a greater prevalence of insulin secretory defects. However, factors underlying the progression of PCOS to T2DM are unclear and may be due to either an increase in the underlying insulin resistance or the progression of beta cell failure. Chapter five described a comparison study between the insulin resistance and beta cell functions in patients with PCOS to that of diet controlled T2DM. I found that the progression from PCOS to the development of T2DM is unlikely to be due to a further increase in insulin resistance (or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production. Having established the effectiveness in the diagnosis of PCOS and its progression, I went on to establish the effectiveness of individual treatments of PCOS. The treatment of patients with PCOS requires that the specific goal(s) of the therapy be first established. Individual goals may include fertility, treatment for hirsutism and/or acne, achieving a regular menstrual cycle, weight reduction and the prevention of the long term consequences associated with PCOS (type 2 diabetes, dyslipidaemia and possibly cardiovascular disease) - or all of the above. Treatments aimed at modifying the long-term consequences on cardiometabolic aspect of PCOS include weight reduction strategies as well as the use of insulin sensitizers. There is currently insufficient data to suggest the superiority of one treatment over another or the use of these medications for treatment of cardiometabolic risks in patients with PCOS. Endothelial dysfunction had been recognised as an early marker for cardiovascular disease and chapter six compared the changes in endothelial function in women treated with either metformin or pioglitazone. I found that pioglitazone significantly improved endothelial function and hs-CRP whereas metformin did not produce significant improvements. Chapter seven evaluates the effects of orlistat, metformin and pioglitazone on metabolic profile and biological variability of IR in women with PCOS. The results showed that only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12 week period of the study. These effects with orlistat were coupled with a significantly reduction in total cholesterol through a reduction in LDL. After conducting the above studies and searching through literatures, I found that studies in cardiometabolic risks in women with PCOS had so far shown conflicting results, and this may be due to the heterogeneity within the group. Chapter eight evaluates this heterogeneity particularly between anovulatory and ovulatory women with PCOS, where all subjects met the Rotterdam criteria. Women with anovulatory PCOS were found to have higher mean and biological variability of IR compared to those having an ovulatory cycle, and both were higher than women without PCOS. This suggests that the subset of patients who ovulate may be better protected against future cardiovascular consequences. In conclusion, this thesis demonstrated that LH/FSH ratio is of no use in the diagnosis of PCOS and that free androgen index appeared to be the best diagnostic marker when compared to total testosterone and bioavailable testosterone.
APA, Harvard, Vancouver, ISO, and other styles
5

Yasmin, Ephia. "Metabolic aspects of polycystic ovary syndrome." Thesis, University of Leeds, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.545722.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Baker, Elizabeth. "Illness Perceptions of Polycystic Ovary Syndrome." Scholar Commons, 2014. https://scholarcommons.usf.edu/etd/5176.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is a chronic illness that affects approximately five million premenopausal women in the United States and is associated with significant cosmetic, reproductive, metabolic, and psychological consequences. Despite its prevalence, few studies have explored the lived experiences and illness perceptions of women living with PCOS. Identifying illness perceptions of women living with (WLW) PCOS is important, because mounting research suggests that a person's perceptions of their chronic illness and its management determine that person's coping behaviors (e.g., adherence, self-management) and, consequently, illness outcomes. In this dissertation, the Common Sense Model (CSM) is used as a framework to identify the illness perceptions of PCOS held by WLW the syndrome. As such, this dissertation is the first to test the ecological validity of the CSM in a population of women diagnosed with PCOS. In addition, the relationship between illness perceptions and (1) infertility, a common symptom of the syndrome, and (2) health-related quality of life (HRQoL) is explored. Lastly, this study makes a novel contribution to the literature by describing one of the first samples of WLW PCOS recruited through a social networking site. This includes a discussion of the participant's demographic information, fertility experiences, and HRQoL. This is a two-phase mixed methods study. Phase one consisted of an online quantitative survey capturing data on 376 participants' demographic information and medical history. Data were also collected on each participant's HRQoL using the SF-36, a generic, well-validated measure of the phenomenon. Of the 376 survey participants, 34 were interviewed via phone or video chat in the fall 2013 and spring 2014 semesters. Quantitative data were downloaded from Qualtrics® and analyzed using SAS statistical software version 9.3. In this analysis, descriptive statistics were generated to describe sample characteristics and SF-36 domain scores were calculated for each participant. In the qualitative analysis, data were analyzed through a series of sorting techniques and transcripts were imported into NVivo 10 and subjected to content analysis. The mean age of survey participants was 31.8 years (SD=5.8). Respondents were primarily non-Hispanic (92.5%), white (88.3%), straight (94.4%), and married (73.4%) with a college education (64.1%). On average, participants reported living with PCOS for 7.6 years (SD=6.1). Approximately half of the sample reported having biological children (47.9%) and currently trying to conceive (42.1%), and most participants reported a history of infertility (70.7%). In addition, almost half of the total sample reported heights and weights that placed them in the morbidly obese category (BMI>35). Lastly, a history of depression (63.6%) and anxiety (68.6%) was common among participants. Few survey participants reported their general health as being excellent (2.6%) or very good (27.4%). Similarly, women reported the lowest levels of functioning on the dimension of vitality, meaning that, in general, women reported feeling tired and being low in energy. Conversely, women reported the highest scores on the dimensions of physical functioning and role limitations due to physical health, meaning that, in general, women did not report that their health limited their physical abilities or caused problems with work or other daily activities. Interview findings suggest that WLW PCOS generally have illness perceptions of the syndrome that are consistent with the domains identified in the CSM. In addition, it was found that, in relation to their illness cognitions, WLW PCOS described the extent to which they felt they had a comprehensive understanding of the syndrome, a phenomenon labeled illness coherence. Similarly, participants identified PCOS as a common condition (i.e. labeled perceived prevalence). Lastly, a number of relationships were identified between illness perceptions and (1) infertility status and (2) HRQoL scores. Overall, this dissertation identifies a number of implications for patient education, provider education, clinical practice, and policy improvements. Examples include addressing (1) unmet information needs, (2) significant psychological morbidity and unmet mental health needs, (3) breastfeeding challenges and need for breastfeeding support, (4) poor quality of care and low patient satisfaction, and (5) limited access to care - all among women living with PCOS.
APA, Harvard, Vancouver, ISO, and other styles
7

Lindholm, Åsa Maria. "Metabolic Aspects in the Polycystic Ovary Syndrome." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-120235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vanky, Eszter. "Polycystic ovary syndrome - Metformin treatment in pregnancy." Doctoral thesis, Norwegian University of Science and Technology, Faculty of Medicine, 2005. http://urn.kb.se/resolve?urn=urn:nbn:no:ntnu:diva-688.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lindholm, Åsa Maria. "Metabolic Aspects in the Polycystic Ovary Syndrome." Doctoral thesis, Uppsala universitet, Institutionen för kvinnors och barns hälsa, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-120235.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of childbearing age and is associated with a number of metabolic disturbances. It has been hypothesised these women carry an increased risk of developing cardiovascular diseases (CVD) with advancing age. The first aim of this thesis was to establish the prevalence of PCOS-related symptoms in Northern Sweden. The Northern part of the WHO MONICA project was used for this purpose. Based on self-reported menstrual disturbances and hirsutism together with biochemical analyses of free androgen index, the estimated prevalence of PCOS in Northern Sweden was 4.8%, which corresponded with previous prevalence studies. Disturbances in the fibrinolytic system are predictors of future cardiovascular events and measurements of plasminogen activator inhibitor 1 (PAI-1) activity and tissue plasminogen activator (tPA) mass concentration may be used to assess fibrinolytic activity in women with PCOS. From the findings, over-weight women with PCOS had impaired fibrinolysis, especially if they displayed objective biochemical markers of hyperandrogenism. Conversely, lean women with PCOS, displayed no signs of disturbed fibrinolysis. The adipose tissue is an active endocrine organ that produces and releases hormones, pro- and anti-inflammatory cytokines, and chemoattractant cytokines. Proinflammatory molecules produced by adipose tissue can be active participants in the development of insulin resistance and the increased risk of cardiovascular disease associated with obesity. The findings suggested being overweight, rather than the PCOS diagnosis per se, was the main explanatory variable for elevated adipose tissue inflammation in PCOS patients. Weight reduction is the primary target for intervention in overweight and obese women with PCOS. When this thesis was planned, no placebo-controlled trials on anti-obesity drugs in women with PCOS had been conducted. Sibutramine in combination with lifestyle intervention resulted in significant weight reduction in overweight women with PCOS. In addition to the weight loss, sibutramine appeared to have a beneficial effect on metabolic and cardiovascular risk factors.
APA, Harvard, Vancouver, ISO, and other styles
10

Gharani, Neda. "The molecular genetics of polycystic ovary syndrome." Thesis, Imperial College London, 2000. http://hdl.handle.net/10044/1/8841.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Polycystic ovary syndrome Pathophysiology"

1

Elsheikh, Mohgah. Polycystic ovary syndrome. Oxford: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Polycystic ovary syndrome. New York: Rosen Central, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Elsheikh, Mohgah. Polycystic ovary syndrome. Oxford: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pal, Lubna, and David B. Seifer, eds. Polycystic Ovary Syndrome. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92589-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pal, Lubna, ed. Polycystic Ovary Syndrome. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-8394-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dunaif, Andrea, R. Jeffrey Chang, Stephen Franks, and Richard S. Legro, eds. Polycystic Ovary Syndrome. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-108-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chang, R. Jeffrey, ed. Polycystic Ovary Syndrome. New York, NY: Springer New York, 1996. http://dx.doi.org/10.1007/978-1-4613-8483-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

FRACOG, Kovacs Gabor MRCOG, and Norman Robert, eds. Polycystic ovary syndrome. 2nd ed. Cambridge: Cambridge University Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

HOMBURG, ROY, and MB BS. Polycystic Ovary Syndrome. Abingdon, UK: Taylor & Francis, 1988. http://dx.doi.org/10.4324/9780203426708.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

S, Jacobs H., ed. Polycystic ovary syndrome. London: Baillière Tindall, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Polycystic ovary syndrome Pathophysiology"

1

Shapiro, Alice J., Vitaly Kushnir, and David B. Seifer. "Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS." In Polycystic Ovary Syndrome, 511–25. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92589-5_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Adashi, Eli Y. "Hyperinsulinemic Androgenism: A Pathophysiologic Paradox." In Polycystic Ovary Syndrome, 245–53. New York, NY: Springer New York, 1996. http://dx.doi.org/10.1007/978-1-4613-8483-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dumont, Agathe, Pauline Plouvier, and Didier Dewailly. "Follicle Excess and Abnormalities in Women with PCOS: Pathophysiology, Assessment and Clinical Role." In Infertility in Women with Polycystic Ovary Syndrome, 89–105. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-45534-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Catteau-Jonard, Sophie, and Didier Dewailly. "Pathophysiology of Polycystic Ovary Syndrome: The Role of Hyperandrogenism." In Frontiers of Hormone Research, 22–27. Basel: S. KARGER AG, 2012. http://dx.doi.org/10.1159/000341679.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Balen, Adam. "Polycystic Ovary Versus Polycystic Ovary Syndrome." In Polycystic Ovary Syndrome, 37–49. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-108-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Agrawal, Sungeeta. "Polycystic Ovary Syndrome." In Endocrine Conditions in Pediatrics, 267–70. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-52215-5_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sherif, Katherine. "Polycystic Ovary Syndrome." In Women’s Health in Clinical Practice, 183–98. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-469-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Johnston-MacAnanny, Erika B., John Kyun Park, and Sarah L. Berga. "Polycystic Ovary Syndrome." In Clinical Reproductive Medicine and Surgery, 113–23. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6837-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wheeler, Catherine J., William R. Keye, and C. Matthew Peterson. "Polycystic Ovary Syndrome." In Reproductive Endocrinology and Infertility, 147–82. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1436-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sood, Minisha, Susan B. Zweig, Marsha C. Tolentino, Marina Strizhevsky, and Leonid Poretsky. "Polycystic Ovary Syndrome." In Principles of Diabetes Mellitus, 1–19. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20797-1_33-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Polycystic ovary syndrome Pathophysiology"

1

Mehrotra, Palak, Chandan Chakraborty, Biswanath Ghoshdastidar, Sudarshan Ghoshdastidar, and Kakoli Ghoshdastidar. "Automated ovarian follicle recognition for Polycystic Ovary Syndrome." In 2011 IEEE International Conference on Image Information Processing (ICIIP). IEEE, 2011. http://dx.doi.org/10.1109/iciip.2011.6108968.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

do Vale, Jessica, Adriana Maria Wan Stadnik, and Frieda Saicla Barros. "FAT DISTRIBUTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME." In XI Simpósio de Engenharia Biomédica. Uberlândia, Minas Gerais: Even3, 2018. http://dx.doi.org/10.29327/xiseb.128378.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bharati, Subrato, Prajoy Podder, and M. Rubaiyat Hossain Mondal. "Diagnosis of Polycystic Ovary Syndrome Using Machine Learning Algorithms." In 2020 IEEE Region 10 Symposium (TENSYMP). IEEE, 2020. http://dx.doi.org/10.1109/tensymp50017.2020.9230932.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yinhui Deng, Yuanyuan Wang, and Ping Chen. "Automated detection of Polycystic Ovary Syndrome from ultrasound images." In 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2008. http://dx.doi.org/10.1109/iembs.2008.4650280.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jayanti, Saktryana Endang Ragil, and Bhisma Murti. "Effect of Obesity on Polycystic Ovary Syndrome: Meta-Analysis." In The 8th International Conference on Public Health 2021. Masters Program in Public Health, Universitas Sebelas Maret, 2021. http://dx.doi.org/10.26911/ab.maternal.icph.08.2021.28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Idacahyati, Keni, Tita Nofianti, and Ema Sintya Nurjaya. "Evaluation of Label Drug in the Treatment Polycystic Ovary Syndrome." In 2nd Bakti Tunas Husada-Health Science International Conference (BTH-HSIC 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200523.032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ahmetasevic, Amila, Lejla Alicelebic, Berina Bajric, Ervina Becic, Alisa Smajovic, and Amar Deumic. "Using Artificial Neural Network in Diagnosis of Polycystic Ovary Syndrome." In 2022 11th Mediterranean Conference on Embedded Computing (MECO). IEEE, 2022. http://dx.doi.org/10.1109/meco55406.2022.9797204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hdaib, Dana, Noor Almajali, Hiam Alquran, Wan Azani Mustafa, Waleed Al-Azzawi, and Ahmed Alkhayyat. "Detection of Polycystic Ovary Syndrome (PCOS) Using Machine Learning Algorithms." In 2022 5th International Conference on Engineering Technology and its Applications (IICETA). IEEE, 2022. http://dx.doi.org/10.1109/iiceta54559.2022.9888677.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

van der Plaat, Diana, Cosetta Minelli, Deborah Jarvis, Judith Garcia-Aymerich, Francisco Gomez-Real, and Bénédicte Leynaert. "Polycystic ovary syndrome and lung function: a Mendelian randomization study." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa5390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mehrotra, Palak, Jyotirmoy Chatterjee, Chandan Chakraborty, Biswanath Ghoshdastidar, and Sudarshan Ghoshdastidar. "Automated screening of Polycystic Ovary Syndrome using machine learning techniques." In 2011 Annual IEEE India Conference (INDICON). IEEE, 2011. http://dx.doi.org/10.1109/indcon.2011.6139331.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Polycystic ovary syndrome Pathophysiology"

1

Yang, Yijiao, Honglin Liu, Yue Xia, Xia Peng, and Xiaorong Ni. Tanshinone for polycystic ovary syndrome: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Li, Li, Jianxiu Yu, and Zhongwei Zhou. Mean platelet volume and polycystic ovary syndrome: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2021. http://dx.doi.org/10.37766/inplasy2021.10.0021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Glintborg, Dorte, Naja Due Kolster, Pernille Ravn, and Marianne Skovsager Andersen. Prospective risk of type 2 diabetes in normal weight women with polycystic ovary syndrome. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0070.

Full text
Abstract:
Review question / Objective: To investigate the risk for type 2 diabetes (T2D) in normal weight women with PCOS. The following PECOs (Population, Exposure, Comparator and Outcome) were included: Population: Pre- and postmenopausal women. Exposure: PCOS Comparator: Healthy control or background population. Outcome: T2D. Condition being studied: Polycystic ovary syndrome (PCOS) is a common endocrine disorder of reproductive-aged women with a prevalence of 15–20%. Polycystic ovary syndrome (PCOS) is most often defined according to the Rotterdam criteria, which include irregular ovulation, biochemical/clinical hyperandrogenism, and/or polycystic ovaries when other causes are excluded.
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Yuanyuan, Zhaoning Duan, Yunpeng Wang, Xiwen He, and Zhi Cheng. Association between the CYP17A1 − 34T/C polymorphism and polycystic ovary syndrome: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pan, Jing, Jianwei Zhang, Shan Xiang, Shangqian Dong, and Xiuyun Qin. A comparison of the efficacy and safety of complementary and alternative therapies for Polycystic Ovary Syndrome. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2021. http://dx.doi.org/10.37766/inplasy2021.1.0077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Huang, Gang, and Bojun Zhou. Intervention effects of four rehabilitation exercises on polycystic ovary syndrome: a Bayesian-based reticulated Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Xu, Kou, Zhongyu Zhou, Wei Huang, Siying Lv, Yanji Zhang, and Chen Wan. Effectiveness and safety of moxibustion treatment for Polycystic Ovary Syndrome: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Miao, Chenyun, Qingge Guo, Xiaojie Fang, Yun Chen, Ying Zhao, and Qin Zhang. Effects of Probiotics and Synbiotics Supplementation on Insulin Resistance in Women with Polycystic Ovary Syndrome: A Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hu, Yan, and YanYing Guo. The effectiveness and safety of exenatide in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lei, Wenwen, Yang Gao, Shiruo Hu, Dongyin Liu, and Qiu Chen. Effects of inositol and alpha lipoic acid combination for polycystic ovary syndrome: a protocol for systematic review and meta-analysis. International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Polycystic ovary syndrome Pathophysiology' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography